“Roflumilast (Daliresp®) to Reduce Acute Pulmonary Events in Fibrotic Sarcoidosis: A Multi-Center, Double Blind, Placebo Controlled, Randomized Clinical Trial”. Sarcoidosis, Vasculitis and Diffuse Lung Diseases, vol. 38, no. 3, Sept. 2021, p. e2021035, https://doi.org/10.36141/svdld.v38i3.11684.